louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06832332: Alternative Birth Positions During the Second Stage
Official title: Midwifery Students' Experiences and Opinions on Alternative Birthing Positions in the Second Stage of Labor
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Simulation
Lead sponsor: Burdur Mehmet Akif Ersoy University
Sponsor class: OTHER
First posted: 2025-02-18
Enrollment: 60
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: Simulation training provided before clinical practice at many universities helps students feel confident and well prepared for the clinical environment. Simulation-based learning not only improves professional competence in midwifery educators but also equips and empowers midwifery students in practice. In undergraduate midwifery education, students are provided obstetric skills training on electronic fetal monitoring (EFM), delivery management, shoulder dystocia, postpartum hemorrhage, breech delivery, umbilical cord prolapse and perineal repair (incision and episiotomy). It has been determined that simulation-based training positively affects the perceived readiness of the participants. It is emphasized that health personnel should be encouraged to freely choose birth positions and be informed about the risks and benefits of upright and supine positions. This study will be conducted to evaluate the effect of midwifery students' use of alternative birth positions in the second stage of labor on students' anxiety, self-efficacy, skill and knowledge levels.


Eligibility criteria: Inclusion Criteria:

* Continuing their third year in the 2024-2025 Spring semester,
* Students who have passed the normal birth management course

Exclusion Criteria:

* Students who fail the normal birth management course

Primary outcomes:
measure: Childbirth Skills Self-Efficacy Scale
timeFrame: 1 HOUR
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03168932: Quantification of Fetal Brains' Sulci Along Gestation
Official title: Detecting and Quantifying Sulci and White Matter in Fetus' Brain Along the Third Stage of Gestation
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Fetal Brain Injury
Lead sponsor: Rambam Health Care Campus
Sponsor class: OTHER
First posted: 2017-05-30
Enrollment: 150
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthy pregnant women between the age of 18-35 at gestational age of 25-40 weeks

Brief summary: Gyrogenesis is an ontogenic process that transforms the smooth (lissencephalic) cortex toward its mature, convolved (gyrencephalic) state. A tortuous, branching and deepening pattern of sulci and fissures outlines for a well-developed cortex.

The aim of this study is to find an algorithm that can detect the sulci in ultrasound images of fetus' brain and measure the length of it. This algorithm can be used for research demands like learning the development of the brain from embryo stages until the birth of the baby


Eligibility criteria: Inclusion Criteria:

* Pregnant women between the ages of 18-35
* Gestational age between 25-40 weeks
* Low risk pregnancies

Exclusion Criteria:

* Multiple gestation
* Fetal brain abnormality

Primary outcomes:
measure: morphological changes of the developing fetal brain
timeFrame: 9 months
Secondary outcomes:
Other outcomes:
Locations:
city: Haifa
country: Israel
facility: Rambam Health Care Campus
Study officials:
References:
Clinical trial NCT03529032: Preoperative Methadone Single Dose Reduces Postoperative Morphine Consumption.
Official title: A Preoperative Methadone Single Dose for Moderately to Severely Painful Surgery Reduces Postoperative Morphine Consumption Results From a Double-blind Pragmatic Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Pain, Postoperative
Keywords: methadone
postoperative pain
acute pain therapy
postoperative pain therapy
Lead sponsor: Kantonsspital Baden
Sponsor class: OTHER
First posted: 2018-05-18
Enrollment: 160
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study was to evaluate the effect of intraoperative methadone on postoperative analgesic requirements, pain scores and patient satisfaction in comparison to standard intraoperative pain control with fentanyl.

Detailed description: Patients of both genders and up to age 75 and ASA classification III were enrolled, when undergoing moderately to severely painful surgery scheduled for ≥90 minutes in general anaesthesia. Patients were randomized to receive either a single shot of methadone (0.2mg/kg) or fentanyl (0.003mg/kg) for induction of anesthesia. In cases of insufficient intraoperative analgesia repeated fentanyl administration was possible. Postoperative analgesia was provided with patient controlled morphine in both groups (PCA = Patient Controlled Analgesia). Pain was assessed using the numerical rating scale (NRS) at rest and after coughing, at 15 minutes post extubation, and repeated every 6 hours up to 72 hours postoperatively. The levels of sedation and nausea/vomiting were also evaluated in parallel.

Eligibility criteria: Inclusion Criteria:

* informed consent
* Patients of both genders and up to age 75 and ASA classification III were enrolled, when undergoing moderately to severely painful surgery scheduled for ≥90 minutes in general anaesthesia.
* german speaking patients

Exclusion Criteria:

* patients including other studies
* pregnant
* breast feeding
* patients in methadone substitution therapy
* dependent drug user
* patients with BMI greater than 36kg/m2
* patients with chronic or acute renal failure with serum creatinine greater than 400µmol/L
* patients with liver insufficiency or failure
* alcoholics
* patients with acute heard attack

Primary outcomes:
measure: Difference of postoperative morphine consumption
timeFrame: first 48 hours postoperatively
Secondary outcomes:
measure: Difference in pain scores, using the Numeric Rating Scale
timeFrame: first 72 hours postoperatively
Other outcomes:
Locations:
city: Baden
country: Switzerland
facility: Kantonsspital Baden
state: Kanton Aargau
Study officials:
affiliation: Kantonsspital Baden
name: Philipp Buehler, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02013232: Adjunctive Aripiprazole in the Treatment of Risperidone-Induced Hyperprolactinemia
Official title: Adjunctive Aripiprazole in the Treatment of Risperidone-Induced Hyperprolactinemia: A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Schizophrenia
Keywords: Risperidone;
Aripiprazole;
Hyperprolactinemia;
dose effects
Lead sponsor: Beijing HuiLongGuan Hospital
Sponsor class: OTHER
First posted: 2013-12-17
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Hyperprolactinemia is a frequent consequence of treatment with typical antipsychotic agents and atypical antipsychotics such as risperidone. Recent studies have suggested that aripiprazole, a partial dopamine agonist, reduces the prolactin response to antipsychotics. Thus, we conducted this study to evaluate the dose effects of adjunctive treatment with aripiprazole on hyperprolactinemia in stable schizophrenic patients maintained with risperidone.


Eligibility criteria: Inclusion Criteria:

1. aged 18-45 years of and fulfilled Diagnostic and Statistical Manual of Mental Disorders(DSM-IV )criteria (American Psychiatric Association, 1994) for schizophrenia;
2. having a stable psychiatric condition, defined as taking the same dosage of risperidone for at least 6 weeks;
3. being treated with risperidone monotherapy; and presence of hyperprolactinemia associated with risperidone.

Exclusion Criteria:

1. any other major psychiatric disorder;
2. significant concurrent medical illnesses, organic brain disorder, history of substance and alcohol abuse, and mental retardation

Primary outcomes:
measure: Prolactin level
timeFrame: baseline, 2 weeks, 4 weeks, 8 weeks
Secondary outcomes:
measure: PANSS (positive and negative syndrome scale) score
timeFrame: Baseline, 8 weeks
Other outcomes:
measure: extrapyramidal symptoms
timeFrame: baseline, 4 weeks, 8 weeks
Locations:
city: Beijing
country: China
facility: Beijing HuiLongGuan Hospital
state: Beijing
Study officials:
References:
Clinical trial NCT00325832: Conventional Versus Automated Measurement of Blood Pressure in the Office (The CAMBO Study)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Hypertension
Keywords: Hypertension
Blood Pressure
Systolic Pressure
Diastolic Pressure
Blood Pressure Monitoring, Ambulatory
Lead sponsor: Sunnybrook Health Sciences Centre
Sponsor class: OTHER
Collaborators: name: Heart and Stroke Foundation of Ontario
First posted: 2006-05-15
Enrollment: 750
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL

Brief summary: To determine if the use of automated office blood pressure readings can improve management of systolic hypertension in routine clinical practice. Automated office SBP recordings in routine clinical practice using the BpTRU device will reflect more accurately the mean awake ambulatory systolic BP than will manual BP readings taken with conventional mercury sphygmomanometry. This should lead to improvements in the management of systolic hypertension with optimization of drug therapy in practices using the BpTRU device.


Eligibility criteria: Inclusion Criteria:

* Both treated and untreated patients with systolic hypertension under routine FP care
* For untreated patients, routine office SBP as measured by the patient's FP at the last routine office visit using a mercury device must have SBP ≥ 160 mmHg and DBP \<= 95 mmHg
* For patients already receiving antihypertensive therapy, the last routine office BP as measured by the patient's FP using mercury sphygmomanometry must be SBP ≥ 140 mmHg and DBP \<= 90 mmHg

Exclusion Criteria:

* Presence of target organ damage such as MI, stroke, and serum creatinine twice normal
* Diabetes mellitus treated with insulin or oral hypoglycemic therapy
* Secondary hypertension
* Participation in another research study involving measurement of BP
* Patient's insistence on using self BP measurement outside of the study
* Any conditions or circumstances which might preclude the successful completion of the study

Primary outcomes:
measure: ambulatory blood pressure
Secondary outcomes:
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: Sunnybrook Health Sciences Centre
state: Ontario
Study officials:
affiliation: Sunnybrook Medical Sciences Centre
name: Martin Myers, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Sunnybrook Health Sciences Centre
name: Sheldon Tobe, MD
role: STUDY_CHAIR
References:
Clinical trial NCT01126632: Will Cap-Assisted Colonoscopy Improve Performance of Colonoscopy: A Randomized Clinical Trial
Official title: Will Cap-Assisted Colonoscopy Improve Performance of Colonoscopy: A Randomized Clinical Trial
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Colonoscopy
Keywords: Colonoscopy
Lead sponsor: Nova Scotia Health Authority
Sponsor class: OTHER
First posted: 2010-05-20
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Endoscopy Clinic- Patients already receiving colonoscopies

Brief summary: Observing the effects of an Olympus cap on the visibility and in adenoma detection during colonoscopy.

Detailed description: To see if Colonoscopy with the CAP is able to give more visibility and to see if detection rate for adenomas, polyps are easier to detect.

Eligibility criteria: Inclusion Criteria:

* Patients already booked for a colonoscopy

Exclusion Criteria:

* History of Colorectal Cancer
* Severe colitis
* Cancer
* poor bowel prep

Primary outcomes:
measure: cap-assisted colonoscopy compared visibility with standard colonoscopy
timeFrame: 4 months
Secondary outcomes:
measure: Polyp detection rate
timeFrame: 4 months
measure: Adenoma Detection
timeFrame: 4 months
measure: Advanced lesion detection rate
timeFrame: 4 months
measure: Cecal Intubation Rate
timeFrame: 4 months
measure: Total time for colonoscopy
timeFrame: 4 months
measure: Complication Rate
timeFrame: 4 months
measure: Procedure indication
timeFrame: 4 months
Other outcomes:
Locations:
city: Halifax
country: Canada
facility: Capital District Health Authority
state: Nova Scotia
Study officials:
affiliation: Nova Scotia Health Authority
name: Donald G MacIntosh, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Lee YT, Lai LH, Hui AJ, Wong VW, Ching JY, Wong GL, Wu JC, Chan HL, Leung WK, Lau JY, Sung JJ, Chan FK. Efficacy of cap-assisted colonoscopy in comparison with regular colonoscopy: a randomized controlled trial. Am J Gastroenterol. 2009 Jan;104(1):41-6. doi: 10.1038/ajg.2008.56.
Clinical trial NCT06116032: Immune Profiling for Cancer Immunotherapy Response
Official title: Immune Profiling for Cancer Immunotherapy Response
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Cancer
Tumor, Solid
Hematologic Malignancy
Blood Cancer
Keywords: Immunotherapy
Lead sponsor: Dartmouth-Hitchcock Medical Center
Sponsor class: OTHER
First posted: 2023-11-03
Enrollment: 1500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Cancer patients who will receive or who are receiving immunotherapy under FDA- approved indication

Brief summary: In patients clinically treated with FDA-approved immunotherapy the investigators will assess the predictive value of pre- and on-treatment 1) immune-methylation profiling across cancer types, and 2) immune-methylation profiling and cytokine profiling within cancer types.


Eligibility criteria: Inclusion Criteria:

* Cancer patients receiving or will receive immunotherapy under FDA- approved indication (e.g. checkpoint inhibitor therapy with pembrolizumab, nivolumab, or ipilimumab, or cellular immunotherapy).
* Participants are eligible regardless of the type of prior therapy (i.e. prior immunotherapy treated participants can be included).

Exclusion Criteria:

* Pregnant women/fetuses/neonates
* Prisoners
* Decision-impaired individuals

Primary outcomes:
measure: Response to therapy
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Lebanon
country: United States
facility: Dartmouth-Hitchcock Medical Center
state: New Hampshire
Study officials:
affiliation: Dartmouth College
name: Brock C Christensen, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Salas LA, Zhang Z, Koestler DC, Butler RA, Hansen HM, Molinaro AM, Wiencke JK, Kelsey KT, Christensen BC. Enhanced cell deconvolution of peripheral blood using DNA methylation for high-resolution immune profiling. Nat Commun. 2022 Feb 9;13(1):761. doi: 10.1038/s41467-021-27864-7.
Clinical trial NCT07015632: ML-Based Multi-Sensor Fall Risk Screening in DMD
Official title: Quantitative Analysis of Upper Extremity Functional Movement of the Upper Extremity in Patients With Duchenne Muscular Dystrophy
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: DMD
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2025-06-11
Enrollment: 30
Sex: ALL
Minimum age (years): 10
Maximum age (years): 30
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: South Korea

Brief summary: This prospective observational study aims to analyze changes in upper extremity functional movement over time in children with Duchenne Muscular Dystrophy (DMD). Thirty patients will be evaluated at three time points (baseline, 6 months, 12 months) using clinical assessments (PUL 2.0, Brooke Scale, grip strength), computer vision-based video analysis, and machine learning algorithms. The goal is to improve future upper limb evaluation methods for non-ambulatory DMD patients. The study includes safety monitoring and adheres to ethical standards, ensuring patient data confidentiality and providing compensation if adverse effects occur.


Eligibility criteria: Inclusion Criteria:

1. Individuals with a confirmed genetic diagnosis of Duchenne Muscular Dystrophy (DMD)
2. Age over 10 and under 30 years
3. Brooke Scale score between 2 and 5
4. Manual muscle test grade below 3 for shoulder abduction muscles

Exclusion Criteria:

1. Individuals who are unable or unwilling to provide informed consent
2. Brooke Scale score of 1 or 6
3. Individuals with cognitive impairments that significantly limit their ability to participate in assessments

Primary outcomes:
measure: Performance of the upper limb module 2.0
timeFrame: baseline - 6 months - 12 months
Secondary outcomes:
measure: Brooke score
timeFrame: baseline - 6 months - 12 months
measure: grip strength
timeFrame: baseline - 6 months - 12 months
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
state: Jongno
Study officials:
References:
Clinical trial NCT02764632: Facilitation of NGT Insertion
Official title: Digital Facilitation of Nasogastric Tube Insertion Under General Anethesia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Nasogasrtic Tube Insertion
Lead sponsor: Mansoura University
Sponsor class: OTHER
First posted: 2016-05-06
Enrollment: 150
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Insertion of a nasogastric tube (NGT) in anesthetized patients can be a disappointing experience. Many techniques have been explained to improve success rate along with increasing safety, such as forward displacement of the larynx, tube rigidity improvement methods, pushing it down directly through pharynx or using a guide tube. Failure of insertion under general anesthesia reached 50% in some publications


Eligibility criteria: Inclusion Criteria:

* all surgicl patients needing NGT insertion

Exclusion Criteria:

* refusal coagulopathy ASA more than 2

Primary outcomes:
measure: NGT insertion success rate
timeFrame: intraoperative
Secondary outcomes:
Other outcomes:
Locations:
city: Mansoura
country: Egypt
facility: Mansoura university
state: Dkahleya
Study officials:
References:
Clinical trial NCT00159237: GR Defect in Peripheral Blood Mononuclear Cells in COPD
Official title: GR Defect in Peripheral Blood Mononuclear Cells in COPD
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Chronic Obstructive Pulmonary Disease
Lead sponsor: Imperial College London
Sponsor class: OTHER
Collaborators: name: AstraZeneca
First posted: 2005-09-12
Enrollment: 0
Sex: ALL
Minimum age (years): 35
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with severe (stage III, Gold) to very severe (stage IV, GOLD) COPD or subjects who are healthy smokers or subjects who are non-smokers

Brief summary: T.to investigate a possible mechanism of the glucocorticosteroid receptors (GR) defect in patients with severe COPD by studying the effect of dexamethasone (Dex) on GR- binding, interleukin production (IL-6/IL-8) and MKP-1 expression in peripheral blood mononuclear cells blood (PBMC)


Eligibility criteria: Inclusion Criteria:

* Patients with severe (stage III, Gold) to very severe (stage IV, GOLD) COPD or subjects who are healthy smokers or subjects who are non-smokers
* Written informed consent

Exclusion Criteria:

* Current upper respiratory tract infections
* Any significant disease or disorder (e.g. cardiovascular, pulmonary (other than asthma), gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical impairment) which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or may influence the results of the study, or the subjects ability to participate in the study
* Subjects not considered capable, as judged by the investigator, of following instructions of the study, e.g. because of a history of alcohol or drug abuse or any other reason

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: London
country: United Kingdom
facility: Section of Airway Disease, Asthma Lab, Imperial College London, Royal Brompton Hospital
Study officials:
affiliation: Imperial College London
name: Sergei A Kharitonov, MD PhD
role: PRINCIPAL_INVESTIGATOR
References: